Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.

Picture this: your brain is a high-performance engine. Over decades, it doesn’t just wear down; it also starts to run hot.